口服联合外用特比萘芬治疗足癣的疗效观察

目的观察口服联合外用特比萘芬治疗足癣的疗效。方法将82例足癣患者随机分为2组,A组42例,口服特比萘芬片联合外用特比萘芬乳膏,疗程1周;B组40例,口服特比萘芬片联合外用特比萘芬乳膏,疗程2周。结果停药后4周,A组治愈率68．70％,有效率90．47％,真菌清除率90．48％;B组治愈率84．15％,有效率95．00％,真菌清除率97．50％;两组治愈率、有效率及真菌清除率比较无显著性差异。结论1周或2周疗程口服联合外用特比萘芬治疗足癣均有效。     

足癣义诊患者临床分析及特比萘芬联合疗法疗效观察

目的分析西京医院皮肤科近3a来每年足癣义诊患者基本情况,并对口服特比萘芬片结合外用特比萘芬乳膏治疗足癣进行疗效分析。方法回顾性分析3a来每年夏天足癣义诊活动中就诊于西京医院皮肤科足癣患者情况。其中2007年义诊患者随机分为3组。I为单纯特比萘芬乳膏治疗组,外用特比萘芬乳膏2次/d×2周;Ⅱ为单纯口服特比萘芬片组,给予口服特比萘芬片（兰美抒片）250mg/d×1周;Ⅲ组给予口服特比萘芬,250mg/d×1周,联合外用特比萘芬乳膏,2次/d×2周。3组分别在患者治疗1个月后电话随访。结果3a足癣义诊周患者平均真菌阳性率为75.76%;采用特比萘芬联合疗法治疗的患者,有效率高达85.26%,复发率不足6%。结论特比萘芬联合疗法治疗足癣疗效肯定。     

口服特比萘芬联合外用药治疗皮肤浅部真菌病137例

目的观察口服特比萘芬联合外用药治疗皮肤浅部真菌病的疗效。方法对137例皮肤浅部真菌病患者应用特比萘芬口服1周(250mg/d)联合外用咪康唑霜1周治疗,观察其临床疗效。结果痊愈126例,显效4例,好转7例,无效0例。总有效率为94.9%,真菌清除率为95.6%。结论口服特比萘芬联合咪康唑霜外用治疗皮肤浅部真菌病有良好的疗效。     

口服特比萘芬联合外用自制双唑霜治疗足癣临床疗效观察

目的观察口服特比萘芬联合外用自制双唑霜治疗足癣的临床疗效。方法57例足癣患者口服特比萘芬0.25g/d,并外用自制双唑霜(主要成分咪康唑与联苯苄唑)2次/d,疗程1周。于停药时、停药4周后分别记录患者皮损情况,不良反应,同时作真菌镜检。结果停药时临床治愈率43.86%,有效率73.68%,真菌清除率78.95%。停药4周后,临床治愈率75.44%,有效率91.23%,真菌清除率96.49%。结论口服特比萘芬联合外用自制双唑霜治疗足癣方便、安全、起效快、患者依从性好,值得临床应用。     

特比萘芬治疗顽固性手、足癣的临床疗效及安全性评价

目的评价特比萘芬治疗顽固性手、足癣的临床疗效及安全性。方法将120例患者随机分为实验组和对照组,实验组口服特比萘芬250mg,1次/d,联合外用特比萘芬乳膏,2次/d,连续3周;对照组患者仅外用特比萘芬乳膏2次/d,连续3周。停药2周后评价最终疗效和不良反应,停药4周后观察复发率。结果停药2周后,实验组患者的临床有效率为95%,真菌学清除率为95%,不良反应发生率为5%（主要为胃肠道反应）;对照组患者的临床有效率为40%,真菌学清除率为75%。停药4周后,实验组患者未见复发,对照组患者复发率为20%。结论口服特比萘芬联合外用特比萘芬乳膏治疗顽固性手、足癣是安全、有效的。     

特比萘芬短程口服加外用特比萘芬治疗中重度皮肤癣菌病的临床对照研究

目的为治疗中、重度皮肤癣菌病选择合适的方法。方法采用开放、随机对照的平行研究。将临床和真菌镜检确诊的中重度体、股癣和手、足癣患者随机分入A、B、C、D四组,A组口服特比萘芬片联合外用特比萘芬乳膏,疗程7d;B组常规口服特比萘芬片,疗程14d;C组常规外用特比萘芬乳膏,疗程14d;D组外用联苯苄唑乳膏,疗程4周。对各组的临床疗效、安全性、患者对治疗的满意度等进行分析。结果①真菌学疗效:停药后4周时A组手、足癣患者的真菌清除率最高为96.65%,与D组比较(65.00%)差异有显著性。②临床疗效:停药后2周和4周时A组手足癣患者的治愈率分别为93.33%和90.00%,与D组(68%、64%)比较差异有显著性。③患者满意度:在本研究的四组中,A组患者对疗效的满意度最高,与C组、D组比较差异有显著性;患者的综合满意度(包括对治疗费用、安全性等方面)A组最高,与C组、D组比较差异有显著性。D组患者对费用的接受程度最高,A组优于B组,有极显著的统计学差异。治疗结束后患者对安全性的接受程度四组间没有显著差异。结论特比萘芬口服加外用1周的“1 1”短程联合疗法治疗中、重度皮肤癣菌病的疗效高、疗程短、依从性好,患者满意度高。     

特比萘芬片联合冰醋酸治疗甲真菌病60例临床疗效观察

甲真菌病是皮肤科临床上常见的疾病之一,其治疗相对困难。为提高疗效,我们对60例甲真菌病患者采用口服特比萘芬片联合外用冰醋酸治疗,观察其临床疗效,现报告如下。     

特比萘芬治疗念珠菌性龟头炎56例临床分析

念珠菌性龟头炎（Penile candidiasis）以往常采用局部治疗，但有时由于治疗不充分而使多数患者复发。特比萘芬治疗浅部真菌病的研究报告较多，但用该药治疗念珠菌病的报告较少，为进一步验证特比萘芬对念珠菌性龟头炎的疗效，我们在临床上予以特比萘芬口服治疗，250mg／d。本研究分1周治疗组和2周治疗组。结果证明，特比萘芬对该病的治疗是有效的，且2周治疗组疗效明显优于1周治疗组（P〈0．05）。     

外用和口服抗真菌药治疗足癣疗效评价

目的分别评价外用和口服抗真菌药治疗足癣的疗效,为足癣治疗提供参考。方法收集国内外已公开发表的有关外用和口服抗真菌药治疗足癣的临床随机对照试验进行分析评价。结果共有24篇文献入选,总病例数为3059例。外用联苯苄唑乳膏的疗效优于咪康唑和克霉唑乳膏;特比萘芬的疗效明显优于克霉唑乳膏;缺乏特比萘芬和联苯苄唑乳膏疗效比较的相关文献。口服特比萘芬(250mg/d,治疗2周)或伊曲康唑(100mg/d,治疗4周)均明显优于安慰剂和灰黄霉素(500mg/d,治疗4周或6周)。结论外用特比萘芬和联苯苄唑乳膏疗效均较理想;口服特比萘芬和伊曲康唑均有较好的临床疗效。     

口服特比萘芬联合外用特比萘芬乳膏治疗足癣83例疗效观察

目的观察口服特比萘芬联合外用特比萘芬治疗足癣的疗效。探讨口服抗真菌药联合外用抗真菌药治疗足癣的疗效。方法足癣患者83例随机分成2组,治疗组45例,口服特比萘芬联合外用特比萘芬乳膏,疗程2周。对照组38例,局部外用特比萘芬乳膏,疗程4周。结果治疗完成4周后治疗组临床治愈率96%,真菌清除率98%;对照组分别为58%、68%。2组临床治愈率、真菌清除率相比,均有显著性差异。结论联合疗法和单一外用药物治疗足癣均有效,但联合疗法起效快、疗程短、效果较好。     

口服特比萘芬联合外用联苯苄唑乳膏治疗足癣长期临床研究

目的 为足癣治疗提供较理想的方案.方法 盐酸特比萘芬250 mg,口服1次/d;1%联苯苄唑乳膏,外用1次/d.250例足癣患者随机入组.A组口服1周加外用1周,B组口服1周加外用2周,C组口服2周加外用1周,D组口服2周加外用2周,E组单独外用4周.在治疗结束时、治疗结束后4周、24周、40周、56周、72周时对各组的疗效、复发率进行评价.结果 在停药后第24周时,A、B、C、D组与E组疗效比较差异有统计学意义.在停药后第40周、56周、72周时,D组与A、B组疗效比较差异也出现统计学意义.在停药后24周、40周时,A、B、C、D组真菌学疗效与E组比较差异有统计学意义.在停药56周、72周时,D组与A、B组真菌学疗效比较差异也出现统计学意义.在停药40周时,A、B、C、D组与E组复发率比较差异有统计学意义.在停药56周、72周时,D组与A、B组复发率比较差异也出现统计学意义.结论 口服特比萘芬2周联合外用1%联苯苄唑乳膏2周治疗足癣的有效率和真菌学疗效最高,复发率最低.     

Nd：YAG1064nm激光、伊曲康唑治疗轻中度甲真菌病近期疗效分析

目的 观察Nd：YAG1064nm激光治疗机、伊曲康唑治疗甲真菌病的有效性及安全性.方法 选取符合入组条件的患者60例,病甲共125个.将60例患者随机分为A、B两组,A组予以Nd：YAG1064nm激光治疗;B组予以伊曲康唑口服治疗.每组均于第8周、第16周、第24周时随访,随访时予以真菌学评价及临床疗效评价.结果 A组第8周、16周、24周有效率分别为78.9％、52.6％、52.6％,B组第8周、16周、24周有效率分别为80.9％、66.2％、67.6％.A、B两组临床疗效差异无统计学意义（P＞0.05）.结论 激光治疗甲真菌病疗效肯定,且元不良反应.在轻中度甲真菌病患者中,激光治疗和药物治疗有效率差异不大.     

桔梗皂苷对烟雾致矽肺患者血清IL-8 和TNF-alpha水平的影响

目的：探究桔梗皂苷对烟雾致矽肺患者血清白介素-8(IL-8)和肿瘤坏死因子-alpha(TNF-alpha)水平的影响。方法：选取我院呼吸科 2012 年6 月到2013 年6 月收治的68 例男性矽肺患者,并将其随机分为2 组。对照组34 例,给于矽肺宁片4 片/ 次,3 次/d,口 服;氨茶碱片0.1 g/ 次,3 次/d,口服;必漱平片16 mg/ 次,3 次/d,口服;舒喘灵片4.8 mg/ 次,3 次/d,口服;疗程24 周。实验组34 例,在常规治疗的基础上应用加用桔梗皂苷胶囊10 g/ 次,3 次/d,口服;疗程24 周。治疗结束后,检测和比较治疗前后两组患者 SaO2、PaO2、PaCO2、血清IL-8 和TNF-alpha的变化情况。结果：治疗后,两组患者的SaO2、PaO2、PaCO2水平均得到改善,实验组以上指 标较改善更为显著,差异具有统计学意义(P<0.05)。治疗后,两组患者的IL-8 和TNF-alpha水平均较治疗前显著下降,且实验组IL-8 和TNF-alpha水平显著低于对照组,差异具有统计学意义(P<0.05)。结论：桔梗皂苷辅助治疗能够显著改善烟雾致矽肺患者的呼吸功 能,降低血清IL-8 和TNF-alpha含量。     

Oral terbinafine for the tinea unguium of the toenails. Efficacy between 12 and 24 weeks of treament.

Terbinafine 250 mg po daily was administered to 21 patients affected by tinea unguium of the toenails. In 14 cases Trichophyton rubrum was the aetiological agent while Trichophyton mentagrophytes var. interdigitale affected the rest. The treatment was administered randomized during 12 or 24 weeks in two groups of 11 (group A) and 10 (group B) patients. The clinical and mycological response was evaluated at week 12, 24 and 48. Adverse events were registered during the therapeutic period. At week 24, 55.5% of patients from group A were cured, only one patient did not improve and cultures were positive. In group B 66.6% were cured and three were clinically improved but cultures were positive. In the last control after 48 weeks the results were similar except one patient of the group B who worsened of his nails lesions. Only one case of acute urticaria was noted, the symptoms disappeared after the withdrawal of terbinafine. Terbinafine per os is a safe and effective antifungal for the treatment of the tinea unguium of the toenails. A period of 12 weeks of administration is enough in most of cases but when T. rubrum is the aetiology relapse could be possible.     

球形孢子丝菌致婴儿固定型孢子丝菌病1例及相关实验研究

报道1例由球形孢子丝菌所致的婴儿固定型孢子丝菌病。患儿女,3个月,因左眼下内侧皮损2个月就诊,皮损脓液标本进行真菌培养,对培养获得菌株进行形态学、生理学和分子生物学鉴定,并进行药物敏感性检测。真菌培养阳性,镜下可见典型的套袖样菌丝。钙调蛋白基因序列分析鉴定为球形孢子丝菌。药敏试验显示特比萘芬和伊曲康唑对该菌株的菌丝相最低抑菌浓度（minimal inhibitorycon centration,MIC）分别为0．5μg／mL和0．5μg／mL;对该菌株的酵母相的MIC值分别为0．25μg／mL和0．5μg／mL。给予患者口服特比萘芬32．5mg／d治疗10周后皮损消退呈瘢痕化修复。依据临床及实验室检查确诊该病例为球形孢子丝菌所致固定型孢子丝菌病,特比萘芬治疗本病例显示较好疗效。     

Update in Antifungal Therapy of Dermatophytosis

Treatment of dermatophyte infection involves primarily oral and/or topical formulations of azoles or allylamines, particularly itraconazole and terbinafine. Topical medications applied once or twice daily are the primary treatment indicated for tinea corporis/cruris, and tinea pedis/manuum. Use of oral antifungals may be practical where the tinea involvement is extensive or chronic, or where application of a topical is not feasible. For tinea unguium (onychomycosis) and tinea capitis, oral therapies are the primary treatments provided. Recently, topical amorolfine and ciclopirox formulations have been approved for use in milder onychomycosis cases, and their role in the treatment of the different clinical forms of onychomycosis is currently being defined. Relapse of infection remains a problem, particularly with tinea pedis/unguium. Appropriate follow-up duration and education of patients on proper foot hygiene are also important components in providing effective therapy.     

Comparison of terbinafine and clotrimazole in treating tinea pedis.

OBJECTIVE--To compare the efficacy and safety of terbinafine 1% cream and clotrimazole 1% cream in the treatment of tinea pedis. DESIGN--Multicentre, double blind parallel group study. SETTING--32 general practices and one hospital. PATIENTS--256 patients with mycologically confirmed tinea pedis. Of the 211 patients evaluable, 107 were randomised to terbinafine (75 male, 32 female; mean (range) age 40 (12-81) years) and 104 to clotrimazole (79 male, 25 female; mean (range) age 36 (12-71) years). INTERVENTIONS--Terbinafine 1% cream applied twice daily for one week and inert cream applied twice daily for the next three weeks. Clotrimazole 1% cream applied twice daily for four weeks. MAIN OUTCOME MEASURES--Mycological cure (negative results on microscopy and culture) and effective treatment (mycological cure plus no or minimal signs and symptoms) measured at weeks 1, 2, 3, 4, and 6. RESULTS--At week four rates of mycological cure were 93.5% for terbinafine and 73.1% for clotrimazole (p = 0.0001); and at week six 97.2% for terbinafine and 83.7% for clotrimazole (p = 0.001). Rates of effective treatment at week 4 were 89.7% for terbinafine and 58.7% for clotrimazole (p = 0.0001); and 89.7% for terbinafine and 73.1% for clotrimazole (p = 0.002) at week 6. CONCLUSION--These results indicate that a one week course of terbinafine 1% cream is more effective in the treatment of tinea pedis than a four week course of clotrimazole 1% cream, both in terms of mycological cure and effective treatment.